Kahira Pharmaceuticals & Chemical Industries Company (EGX: CPCI)
Egypt
· Delayed Price · Currency is EGP 100.25
-3.37 (-3.25%)
At close: Jan 27, 2025
EGX: CPCI Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 1,448 | 1,361 | 1,005 | 1,112 | 1,062 | 1,010 | Upgrade
|
| Revenue Growth (YoY) | 44.01% | 35.38% | -9.61% | 4.71% | 5.11% | 4.93% | Upgrade
|
| Cost of Revenue | 910 | 843.19 | 767.94 | 785.17 | 793.91 | 750.02 | Upgrade
|
| Gross Profit | 537.64 | 517.66 | 237.3 | 326.95 | 268.13 | 260.41 | Upgrade
|
| Selling, General & Admin | 121.28 | 116.67 | 103.71 | 101.75 | 87.62 | 98.97 | Upgrade
|
| Other Operating Expenses | 114 | 115.32 | 56.85 | 33.11 | 24.18 | 22.67 | Upgrade
|
| Operating Expenses | 235.28 | 231.99 | 160.56 | 134.86 | 111.8 | 121.64 | Upgrade
|
| Operating Income | 302.35 | 285.67 | 76.74 | 192.08 | 156.33 | 138.77 | Upgrade
|
| Interest Expense | -18.85 | -18.94 | -3.47 | - | - | - | Upgrade
|
| Interest & Investment Income | 17.93 | 14.68 | 4.36 | 6.87 | 3.89 | 3.15 | Upgrade
|
| Currency Exchange Gain (Loss) | 27.81 | 27.81 | 45.83 | - | - | -2.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.61 | 6.13 | 4.01 | 15.14 | 2.84 | 2.96 | Upgrade
|
| EBT Excluding Unusual Items | 334.85 | 315.35 | 127.48 | 214.1 | 163.06 | 142.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0 | 0.08 | - | - | -0.01 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -1.37 | Upgrade
|
| Pretax Income | 334.85 | 315.35 | 127.56 | 214.1 | 163.06 | 141.39 | Upgrade
|
| Income Tax Expense | 73.56 | 69.24 | 30.47 | 48.35 | 38.75 | 32.25 | Upgrade
|
| Earnings From Continuing Operations | 261.28 | 246.11 | 97.09 | 165.74 | 124.3 | 109.14 | Upgrade
|
| Net Income | 261.28 | 246.11 | 97.09 | 165.74 | 124.3 | 109.14 | Upgrade
|
| Net Income to Common | 261.28 | 246.11 | 97.09 | 165.74 | 124.3 | 109.14 | Upgrade
|
| Net Income Growth | 169.11% | 153.48% | -41.42% | 33.34% | 13.89% | 28.14% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | 0.13% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 17.47 | 16.48 | 6.50 | 11.10 | 8.32 | 7.31 | Upgrade
|
| EPS (Diluted) | 17.47 | 16.48 | 6.50 | 11.10 | 8.32 | 7.31 | Upgrade
|
| EPS Growth | 168.77% | 153.48% | -41.42% | 33.34% | 13.89% | 28.14% | Upgrade
|
| Free Cash Flow | 19.24 | 19.35 | 9.45 | 34.52 | 138.57 | -30.3 | Upgrade
|
| Free Cash Flow Per Share | 1.29 | 1.30 | 0.63 | 2.31 | 9.28 | -2.03 | Upgrade
|
| Dividend Per Share | 12.830 | 12.830 | 5.000 | 5.000 | 4.000 | 2.680 | Upgrade
|
| Dividend Growth | 156.60% | 156.60% | 0% | 25.00% | 49.25% | - | Upgrade
|
| Gross Margin | 37.14% | 38.04% | 23.61% | 29.40% | 25.25% | 25.77% | Upgrade
|
| Operating Margin | 20.89% | 20.99% | 7.63% | 17.27% | 14.72% | 13.73% | Upgrade
|
| Profit Margin | 18.05% | 18.09% | 9.66% | 14.90% | 11.70% | 10.80% | Upgrade
|
| Free Cash Flow Margin | 1.33% | 1.42% | 0.94% | 3.10% | 13.05% | -3.00% | Upgrade
|
| EBITDA | 318.8 | 301.14 | 88.3 | 207.25 | 156.77 | 139.42 | Upgrade
|
| EBITDA Margin | 22.02% | 22.13% | 8.78% | 18.64% | 14.76% | 13.80% | Upgrade
|
| D&A For EBITDA | 16.45 | 15.47 | 11.56 | 15.17 | 0.44 | 0.65 | Upgrade
|
| EBIT | 302.35 | 285.67 | 76.74 | 192.08 | 156.33 | 138.77 | Upgrade
|
| EBIT Margin | 20.89% | 20.99% | 7.63% | 17.27% | 14.72% | 13.73% | Upgrade
|
| Effective Tax Rate | 21.97% | 21.96% | 23.88% | 22.58% | 23.77% | 22.81% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.